Below are the most recent publications written about "Polyethylene Glycols" by people in Profiles.
-
Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
-
Chelluri LK, Mohanram Y, Jain R, Mallarpu CS, Ponnana M, Kumar D, Krishna Venuganti VV, Kancherla R, Papineni RV, Towner R, Ghosal P. Effect of engineered superparamagnetic iron oxide nanoparticles in targeted cardiac precursor cell delivery by MRI. Biochem Biophys Res Commun. 2021 02 19; 541:15-21.
-
Seaberg J, Kaabipour S, Hemmati S, Ramsey JD. A rapid millifluidic synthesis of tunable polymer-protein nanoparticles. Eur J Pharm Biopharm. 2020 Sep; 154:127-135.
-
Seaberg J, Flynn N, Cai A, Ramsey JD. Effect of redox-responsive DTSSP crosslinking on poly(l-lysine)-grafted-poly(ethylene glycol) nanoparticles for delivery of proteins. Biotechnol Bioeng. 2020 08; 117(8):2504-2515.
-
Natfji AA, Nikitin DO, Semina II, Moustafine RI, Khutoryanskiy VV, Lin H, Stephens GJ, Watson KA, Osborn HMI, Greco F. Conjugation of haloperidol to PEG allows peripheral localisation of haloperidol and eliminates CNS extrapyramidal effects. J Control Release. 2020 06 10; 322:227-235.
-
Elechalawar CK, Hossen MN, Shankarappa P, Peer CJ, Figg WD, Robertson JD, Bhattacharya R, Mukherjee P. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Int J Nanomedicine. 2020; 15:991-1003.
-
Wise HC, Iyer GV, Moore K, Temkin SM, Gordon S, Aghajanian C, Grisham RN. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
-
Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer JE, Ai WZ. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.
-
Wang L, Wang M, Zhou B, Zhou F, Murray C, Towner RA, Smith N, Saunders D, Xie G, Chen WR. PEGylated reduced-graphene oxide hybridized with Fe3O4 nanoparticles for cancer photothermal-immunotherapy. J Mater Chem B. 2019 12 14; 7(46):7406-7414.
-
Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.